*September 2024*
“Firmonertinib has shown promising antitumor activity in a broad range of EGFR PACC-mutant NSCLC,” David Planchard, MD, PhD, thoracic oncologist and head of the Thoracic Pathology Committee at Gustave Roussy in Villejuif, France, and president of the International Center for Thoracic Cancers, said in his presentation. “At 240 mg, firmonertinib showed a confirmed overall response rate [ORR] of 63.6% with encouraging central nervous system [CNS] antitumor activity in this PACC mutation–[positive population].”
In the phase 1b, open-label, multicenter FURTHER trial (FURMO-002), patients received firmonertinib, an oral EGFR inhibitor, in stage 1 cohort 1 for dose escalation and backfill or stage 2 cohort 2, 3, or 4 for dose expansion.
Planchard discussed stage 2 cohort 4, also called the PACC cohort, of 60 patients with EGFR tyrosine kinase inhibitor (TKI) naive, locally advanced or metastatic NSCLC with EGFR PACC mutations. Those in the PACC cohort were randomly assigned 1:1 to receive firmonertinib at 160 mg once a day (n = 31) vs 240 mg once a day (n = 29) until progression, intolerable toxicity, or death.
The median age was 65 years in the 160-mg arm and 68 years in the 240-mg arm. Most patients had ECOG performance status of 1, were nonsmokers, and were Asian. Prior metastatic therapies included chemotherapy in 12.9% and 17.2% of the 160-mg and 240-mg groups, respectively, and other therapies were used in 6.5% and 6.9% of the respective groups. Read more.
